Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers

NCT02451553 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT02451553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02451553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Completed
Start date
November 5, 2015
Completion date
April 16, 2022
Enrollment
41 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, bile duct carcinoma, recurrent malignant solid neoplasm, recurrent pancreatic carcinoma, stage iii pancreatic cancer ajcc v6 and v7, stage iva pancreatic cancer, stage ivb pancreatic cancer